Innocom Bio Equities

InnoCom's investment fund offers a unique opportunity to contribute to critical medical advancements, with a current portfolio of thirteen companies that have invested over $165 million in solutions for cancer, COVID-19, and more. The fund is projected to deliver substantial returns, with outside experts estimating a six-year valuation of $350 billion and very attractive potential investor returns as well. InnoCom's Principals, experienced C-level executives, actively support each portfolio company, enabling them to focus more specifically on scientific innovation and sustainable product realization. The fund's risk is mitigated by its diversity, hands on Strategic and Operational care and an early commercialization strategy bolstered by strong ties with the veterinary community on the way to human clinical approval worldwide.